A new piece to the puzzle sheds light on how UHRF1 regulates gene activity

November 06, 2018

Epigenetic changes often play an important role in cancer, because they cause the genetic material to be read incorrectly at certain locations. Genes that are especially critical are those that control the growth and death of cells. Scientists at Helmholtz Zentrum München have now discovered new details about the UHRF1 protein. UHRF1 catalyses particular steps that are required for marking DNA with epigenetic modifications that suppress parts of the genome. As reported in Molecular Cell, the molecule may serve as a target for drug therapies because it is produced at elevated levels in cancer cells.

All the cells in our body have the same complement of genes yet perform entirely different functions. This is because genes are read differently depending on the type of cell in which they occur. Gene activity is regulated not only at the level of the DNA sequence but also at the epigenetic level by a variety of chemical modifications made to DNA and histones. "Histones are proteins that 'package' the DNA strands in the nucleus into chromosomes. But they also play an important role in controlling gene expression", says Prof. Dr. Robert Schneider, Director of the Institute of Functional Epigenetics (IFE) at Helmholtz Zentrum München. Together with other proteins, DNA molecules and histones form chromatin. This constitutes a chemical method for condensing genetic information within the small space of the cell nucleus. Very little is known about these regulatory processes that are the focus of the research at IFE.

UHRF1: a molecule controls key steps in DNA methylation

Researchers know, however, that the protein UHRF1 (Ubiquitin-like, containing PHD and RING finger domains) plays an important role in the methylation of DNA strands. Methyl tags are chemical modifications to a DNA molecule that do not alter the genetic code, i.e. the sequence of bases of the DNA. However, they affect the activity of genes encoded in the base sequence. Methylation of DNA molecules usually acts to repress gene transcription.

UHRF1 controls DNA methylation by ensuring that an enzyme which attaches methyl groups to DNA can bind to newly formed chromatin. To accomplish this task, UHRF1 must first bind to newly formed chromatin itself and, in a second step, transfer an ubiquitin molecule (a small protein that alters the properties of other proteins) to a histone protein. To this end, UHRF1 uses various protein domains, regions with special three-dimensional structures and functions in the same molecule.

"It was not previously known exactly how this works," says Dr. Till Bartke, Deputy Director of the IFE, who supervised the study. Together with his colleague Dr. Benjamin Foster (post-doctoral researcher at the IFE), he has applied various methods in a bid to shed light on this ubiquitin-transfer step, including chemical crosslinking of molecules, mass spectroscopic studies and the use of recombinant chromatin molecules that were modified with methyl groups. "We found that an ubiquitin-like domain (UBL) must be present to transfer ubiquitin molecules", Bartke says. This is a special structural element involved in rearrangements of UHRF1 after it has bound to chromatin. In collaboration with a research group led by Dr. Sebastian Bultmann at Ludwig-Maximilians University Munich, the researchers were also able to show that the UBL domain is required for the methylation of DNA in cells.

"Our analysis of the enzymatic mechanism of UHRF1 reveals an unexpected function of the UBL domain and defines a new role of this domain in DNA methylation," the scientist explains. Because other groups have found elevated concentrations of UHRF1 in several cancers, including lung and colorectal cancer, the protein, he believes, is well-suited as a target for future therapies.
-end-
Further Information

Original Publication:


Foster, B. M. et al. (2018): Critical role of the UBL domain in stimulating the E3 ubiquitin ligase activity of UHRF1 toward chromatin. Molecular Cell, DOI: 10.1016/j.molcel.2018.09.028

As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,300 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www.helmholtz-muenchen.de/en

The Institute of Functional Epigenetics is interested in how genes are packaged within the nucleus of a cell. The focus is on the so-called "histone proteins" on which the DNA strands are wound and that can determine whether a gene can be read or not. In addition, we are examining the connections between common diseases and distortions in DNA packing. We utilize cutting edge methods that enable us to follow changes of these processes even in individual cells. http://www.helmholtz-muenchen.de/ife/index.html

Contact for the media:

Department of Communication, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 2238 - E-mail: presse@helmholtz-muenchen.de

Scientific Contact at Helmholtz Zentrum München:

Dr. Till Bartke, Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Functional Epigenetics, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 1553, E-mail: till.bartke@helmholtz-muenchen.de

Helmholtz Zentrum München - German Research Center for Environmental Health

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.